Want to see HK:3681 full AI Analyst Report?
SinoMab Bioscience Ltd. (3681) Ratios
SinoMab Bioscience Ltd. Ratios
HK:3681's free cash flow for Q2 2026 was $-53.85M. For the 2026 fiscal year, HK:3681's free cash flow was decreased by $-20.49M and operating cash flow was $-33.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.91 | 0.91 | 1.56 | 2.39 | 6.06 |
| Quick Ratio | 1.91 | 0.91 | 1.56 | 2.39 | 6.06 |
| Cash Ratio | 1.63 | 0.30 | 1.18 | 1.84 | 5.72 |
| Solvency Ratio | -0.19 | -0.30 | -0.37 | -0.54 | -0.77 |
| Operating Cash Flow Ratio | -0.35 | -0.64 | -0.78 | -1.60 | -1.50 |
| Short-Term Operating Cash Flow Coverage | -0.52 | -1.16 | -2.01 | -9.88 | -29.41 |
| Net Current Asset Value | $ -10.34M | $ -374.85M | $ -282.02M | $ -51.68M | $ 234.26M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.37 | 0.64 | 0.53 | 0.35 | 0.26 |
| Debt-to-Equity Ratio | 0.67 | 2.50 | 1.53 | 0.70 | 0.40 |
| Debt-to-Capital Ratio | 0.40 | 0.71 | 0.60 | 0.41 | 0.29 |
| Long-Term Debt-to-Capital Ratio | 0.27 | 0.61 | 0.52 | 0.32 | 0.22 |
| Financial Leverage Ratio | 1.79 | 3.90 | 2.87 | 1.98 | 1.53 |
| Debt Service Coverage Ratio | -0.51 | -1.18 | -2.74 | -8.03 | -27.39 |
| Interest Coverage Ratio | -23.16 | -18.63 | -34.87 | 0.00 | -52.54 |
| Debt to Market Cap | 0.22 | 0.38 | 0.25 | 0.17 | 0.09 |
| Interest Debt Per Share | 0.28 | 0.46 | 0.45 | 0.36 | 0.28 |
| Net Debt to EBITDA | -0.07 | -2.94 | -1.23 | -0.05 | 0.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 26.80% | 30.92% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | -7992.40% | -17327.99% | -6421.80% | -1147.38% |
| EBITDA Margin | 0.00% | -7047.98% | -14685.93% | -6058.85% | -1112.01% |
| Operating Profit Margin | 0.00% | -7964.22% | -16818.68% | -6421.80% | -1147.38% |
| Pretax Profit Margin | 0.00% | -9138.25% | -17810.33% | -7047.57% | -1081.12% |
| Net Profit Margin | 0.00% | -9138.25% | -17810.33% | -7047.57% | -1081.12% |
| Continuous Operations Profit Margin | 0.00% | -9138.25% | -17810.33% | -7047.57% | -1081.12% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 82.01% | 114.74% | 105.90% | 109.74% | 94.23% |
| Return on Assets (ROA) | -11.26% | -24.58% | -28.68% | -28.18% | -27.67% |
| Return on Equity (ROE) | -20.13% | -95.97% | -82.25% | -55.76% | -42.37% |
| Return on Capital Employed (ROCE) | -17.70% | -29.36% | -34.00% | -31.54% | -32.42% |
| Return on Invested Capital (ROIC) | -14.73% | -23.90% | -30.76% | -29.87% | -32.00% |
| Return on Tangible Assets | -11.26% | -24.61% | -28.74% | -28.25% | -27.72% |
| Earnings Yield | -6.92% | -16.84% | -15.69% | -17.92% | -12.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.05 | 0.01 | 0.01 | 0.04 |
| Cash Conversion Cycle | 0.00 | 0.00 | 1627.66 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 1627.66 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 1627.66 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.06 | -0.12 | -0.13 | -0.30 | -0.15 |
| Free Cash Flow Per Share | -0.08 | -0.16 | -0.23 | -0.42 | -0.35 |
| Dividend Paid and CapEx Coverage Ratio | -2.79 | -3.15 | -1.29 | -2.67 | -0.74 |
| Capital Expenditure Coverage Ratio | -2.79 | -3.15 | -1.29 | -2.67 | -0.74 |
| Operating Cash Flow Coverage Ratio | -0.21 | -0.27 | -0.30 | -0.84 | -0.53 |
| Operating Cash Flow to Sales Ratio | 0.00 | -64.56 | -98.06 | -74.54 | -5.52 |
| Free Cash Flow Yield | -6.48% | -15.68% | -15.34% | -26.07% | -14.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.43 | -5.94 | -6.37 | -5.58 | -8.04 |
| Price-to-Sales (P/S) Ratio | 0.00 | 542.51 | 1135.40 | 393.20 | 86.93 |
| Price-to-Book (P/B) Ratio | 2.91 | 5.70 | 5.24 | 3.11 | 3.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.42 | -6.38 | -6.52 | -3.84 | -6.71 |
| Price-to-Operating Cash Flow Ratio | -20.96 | -8.40 | -11.58 | -5.28 | -15.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.28 | 0.20 | 0.37 | 0.00 | -0.06 |
| Enterprise Value Multiple | -20.55 | -10.64 | -8.96 | -6.54 | -6.85 |
| Enterprise Value | 1.48B | 1.52B | 1.80B | 1.60B | 2.03B |
| EV to EBITDA | -20.55 | -10.64 | -8.96 | -6.54 | -6.85 |
| EV to Sales | 0.00 | 750.00 | 1316.46 | 396.04 | 76.14 |
| EV to Free Cash Flow | -15.47 | -8.82 | -7.56 | -3.86 | -5.88 |
| EV to Operating Cash Flow | -21.03 | -11.62 | -13.43 | -5.31 | -13.80 |
| Tangible Book Value Per Share | 0.41 | 0.18 | 0.29 | 0.51 | 0.68 |
| Shareholders’ Equity Per Share | 0.41 | 0.18 | 0.29 | 0.51 | 0.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net Income Per Share | -0.08 | -0.17 | -0.24 | -0.29 | -0.29 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.82 | 1.14 | 1.03 | 1.10 | 0.94 |
| Research & Development to Revenue | 0.00 | 46.77 | 99.20 | 44.73 | 7.47 |
| SG&A to Revenue | 0.00 | 33.42 | 71.39 | 20.44 | 4.95 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 13.92 | 1.24 | 2.36 |
| Income Quality | 0.67 | 0.71 | 0.55 | 1.06 | 0.51 |
Currency in CNY